Advaxis (ADXS) Rating Reiterated by HC Wainwright

Share on StockTwits

HC Wainwright restated their buy rating on shares of Advaxis (NASDAQ:ADXS) in a report issued on Wednesday, The Fly reports.

Separately, Jefferies Financial Group lowered shares of Advaxis from a buy rating to a hold rating and lowered their price target for the stock from $9.00 to $2.00 in a research report on Wednesday, June 13th.

NASDAQ:ADXS opened at $0.81 on Wednesday. Advaxis has a 52 week low of $0.77 and a 52 week high of $5.20.

In other news, Director Roni Appel acquired 33,333 shares of Advaxis stock in a transaction on Tuesday, September 11th. The shares were purchased at an average cost of $1.20 per share, for a total transaction of $39,999.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 7.21% of the company’s stock.

A number of institutional investors have recently made changes to their positions in ADXS. LMR Partners LLP acquired a new stake in Advaxis during the second quarter worth about $171,000. Franklin Street Advisors Inc. NC acquired a new stake in Advaxis during the second quarter worth about $190,000. Paloma Partners Management Co acquired a new stake in Advaxis during the second quarter worth about $265,000. DAFNA Capital Management LLC grew its stake in Advaxis by 182.2% during the first quarter. DAFNA Capital Management LLC now owns 697,000 shares of the biotechnology company’s stock worth $1,178,000 after buying an additional 450,000 shares in the last quarter. Finally, BlackRock Inc. grew its stake in Advaxis by 28.2% during the first quarter. BlackRock Inc. now owns 2,925,417 shares of the biotechnology company’s stock worth $4,943,000 after buying an additional 644,201 shares in the last quarter. Hedge funds and other institutional investors own 21.55% of the company’s stock.

About Advaxis

Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.

Read More: Dividend Stocks – Are They Right For You?

The Fly

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply